Pfizer Inc. (PFE)[Tv]
Monthly Analysis
Sector: Healthcare
Key Developments
-
Pfizer reports strong Q2 2026 results with $15.03B in revenue and $0.77 EPS, beating consensus for the seventh consecutive quarter, marking a pivotal milestone in its post-pandemic transformation and signaling sustained execution excellence beyond pandemic-era products.
-
FDA accepts Priority Review for TALZENNA in combination with XTANDI for mCSPC, a high-value early-stage oncology indication, representing a major regulatory validation of Pfizer’s innovation strategy and potential to unlock billions in new revenue.
-
Pfizer upgrades full-year 2026 revenue guidance to $60.5B–$62.5B, a $500M increase, despite a $0.10 charge from the Innovent deal—demonstrating confidence in its strategic pivot and non-COVID franchise momentum.
This content is for informational purposes only and does not constitute financial, investment, or trading advice. Always consult a qualified financial professional before making any investment decisions.